rho Guanine Nucleotide Dissociation Inhibitor gamma

A rho GDP-dissociation inhibitor subtype that has a unique C-terminal alpha helical membrane-binding domain. It is found bound to CYTOPLASMIC VESICLES such as those associated with the GOLGI APPARATUS.

Also Known As:

Networked: 7 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Lai, Ming-Chun: 1 article (08/2017)
2.	Owusu-Ansah, Kwabena-Gyabaah: 1 article (08/2017)
3.	Wu, Li-Ming: 1 article (08/2017)
4.	Xie, Hai-Yang: 1 article (08/2017)
5.	Yang, Zhe: 1 article (08/2017)
6.	Zheng, Shu-Sen: 1 article (08/2017)
7.	Zhou, Lin: 1 article (08/2017)
8.	Zhu, Qian-Qian: 1 article (08/2017)
9.	Zhu, Yang-Bo: 1 article (08/2017)
10.	Almaraz-Salinas, Manuel: 1 article (01/2016)

Related Diseases

1.	Neointima 11/19/2023 - "The results of this study reveal a novel mechanism through which RhoGDI3 regulates VSMC phenotypic modulation and neointima formation by activating the NLRP3 inflammasome." 11/19/2023 - "The in vivo results also confirmed that RhoGDI3 expressed in VSMCs participated in neointima formation and muscle fiber and collagen deposition caused by balloon injury. " 11/19/2023 - "The pathological roles and mechanisms of Rho-specific guanine nucleotide dissociation inhibitor 3 (RhoGDI3) in vascular smooth muscle cell (VSMC) phenotypic modulation and neointima formation are currently unknown. " 11/19/2023 - "RhoGDI3 at the trans-Golgi network participates in NLRP3 inflammasome activation, VSMC phenotypic modulation, and neointima formation." 11/19/2023 - "This study aimed to investigate how RhoGDI3 regulates the Nod-like receptor protein 3 (NLRP3) inflammasome in platelet-derived growth factor-BB (PDGF-BB)-induced neointima formation. "
2.	Breast Neoplasms (Breast Cancer) 12/15/2003 - "Patients with recurrent disease, with metastasis or who died of breast cancer, also exhibited higher levels of Rho-6 but lower levels of Rho-GDI-gamma. " 12/15/2003 - "This study determined the levels of expression and the distribution of Rho-A, -B, -C, and -G, and Rho-6, -7, and -8, as well as Rho-GDI-beta, and Rho-GDI-gamma, in breast cancer and assessed their prognostic value. "
3.	Neoplasms (Cancer) 01/01/2016 - "Through immunofluorescences, pulldown assays and subcellular fractionation, we found a reduction in RhoGDI3 expression in the late stages of PDAC, and this reduction correlates with tumor progression and aggressiveness. " 01/01/2016 - "However, the role of RhoGDI3 has not been studied in relation to cancer or to PDAC. " 12/15/2003 - "The levels of Rho-GDI-gamma transcripts were found to be significantly lower in tumor tissues than in normal tissues (P < 0.05 and P < 0.001, respectively). " 12/24/2007 - "We then apply the FLIM system to detect the molecular interaction of a transforming oncogene RhoC with a binding partner RhoGDIgamma in vivo, which is critical to understand and interfere with Rho signaling for cancer therapeutics." 08/01/2017 - "However, the level of RhoGDI3 was identified to be similar in tumor and para-carcinoma tissues. "
4.	Squamous Cell Neoplasms (Squamous Cell Cancer) 08/20/2008 - "[Expression of RhoC and its regulators RhoGDIbeta RhoGDIgamma and their clinical importance in lung squamous cell cancer and adenocarcinoma.]."
5.	Neoplasm Metastasis (Metastasis) 12/15/2003 - "Patients with recurrent disease, with metastasis or who died of breast cancer, also exhibited higher levels of Rho-6 but lower levels of Rho-GDI-gamma. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	rho-Specific Guanine Nucleotide Dissociation Inhibitors
3.	Inflammasomes
4.	Becaplermin (PDGF-BB)
5.	NLR Proteins
6.	Rho Guanine Nucleotide Exchange Factors
7.	rho Guanine Nucleotide Dissociation Inhibitor beta
8.	Transforming Growth Factor beta (TGF-beta)
9.	Messenger RNA (mRNA)
10.	Guanine Nucleotides

Related Therapies and Procedures

1.	Therapeutics